Centering discussion on the third patient case, panelists review second-line therapy options for those who relapse with blastic plasmacytoid dendritic cell neoplasm.
Videos
Mark R. Litzow, MD, discusses the talk he gave on initial treatment options for patients with acute lymphoblastic leukemia during the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.
Eytan M. Stein, MD, discusses the currently available treatment options for patients with acute myeloid leukemia and how Menin inhibitors fit into this space.
Nurse Practitioner Lauren Welch and Dr Michelle Shiller share whether next-generation sequencing is reflexively ordered at their institutions, turnaround times for this type of testing, and which panels they typically choose.
Drs Shiller and Piotrowska discuss use of broad genomic profiling according to the patient’s histologic subtype of NSCLC.
Gene G. Finley, MD, discusses the potential use of molecular testing to improve outcomes for patients with relapsed small cell lung cancer.
Dr Lori Wirth reviews real-world outcomes data on lenvatinib treatment in patients with RAI-R-DTC and how they compare to the SELECT trial.
Dr Wirth reviews the updated NCCN guidelines that gave lenvatinib a category 1 recommendation for first-line treatment in advanced RAI-R-DTC and shares her experience of lenvatinib in clinical practice.
A key opinion leader explains the adverse events usually seen with lenvatinib treatment in patients with RAI-R-DTC, and the best management strategies.
Lori Wirth, MD, describes the available treatment options for patients with advanced RAI-R-DTC who progress after first-line treatment with lenvatinib.
Dr Lori Wirth highlights exciting clinical trials in advanced RAI-R-DTC and investigational agents to look out for in the future.
Lori Wirth, MD, provides a brief overview of advanced radioactive iodine-refractory differentiated thyroid cancer, or RAI-R-DTC.
Cyrus M. Kahn, MD, discusses the evolution of the treatment landscape for patients with mantle cell lymphoma.
Robert J. Soiffer, MD, discusses the use of transplant in various hematologic malignancies.
A lung cancer expert describes the common adverse events he sees with immunotherapy in mNSCLC, and the available management strategies.
Edward B. Garon, MD, MS, shares his biomarker testing protocols for patients with NSCLC and highlights the most important biomarkers for guiding therapy.
Dr Edward B. Garon explains the rationale for treating patients with mNSCLC with a frontline combination of chemotherapy and immune checkpoint inhibitors.
Closing the program, Edward B. Garon, MD, MS, shares his view on the implications of recent mNSCLC data in clinical practice, and the unmet needs the field must focus on in the future.
Dr Garon continues with an explanation of the updated analysis of the POSEIDON trial presented at the 2022 World Conference on Lung Cancer.
A key opinion leader reviews the study design and efficacy and safety outcomes of the POSEIDON trial investigating durvalumab + tremelimumab + chemotherapy for treatment of mNSCLC.
Erika P. Hamilton, MD, discusses the purpose of a safety follow-up analysis for the DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.
Alexander Spira, MD, PhD, FACP, discusses the rationale for combining amivantamab-vmjw and lazertinib for the treatment of relapsed or refractory EGFR-mutant non–small cell lung cancer.
In the first installment of this series, Joshua Sabari, MD, provides an overview on the use of chemotherapy for first-line treatment of NSCLC, and discusses how the more recent availability of PD-1/PD-L1– and CTLA-4–targeted immunotherapy is changing the field.
David Morris, MD, FACS, discusses how PSMA PET imaging may impact targeted therapies for prostate cancer in the future.
Bradley A. McGregor, MD, discusses current and future second-line therapy options following frontline tyrosine kinase inhibitor and immunotherapy for patients with advanced renal cell carcinoma.
Dr Bardia provides his opinion on the current state of the ER+/HER2- treatment landscape and where elacestrant belongs in the current treatment paradigm.
Joshua J. Meeks, MD, discusses investigational targets in the bladder cancer space.
Expert panelists review the case of a 22-year-old woman diagnosed with BPDCN and consider the role of first-line chemotherapy in this setting.
Before closing out their review of polycythemia vera management, expert hematologist-oncologists highlight novel therapies in the pipeline.
Closing out their discussion on the first patient case of BPDCN, panelists consider which factors best inform the optimal selection of frontline therapy.